Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 4/20 | 0.34 |
| ▸ | CTSL | P07711 | 3/20 | 0.34 |
| ▸ | CTSB | P07858 | 3/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 2/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147842 | 1.00 | GPR119 (0.37) | GPR119RAF1CTSSCTSLCTSB | |
| SCHEMBL30147823 | 0.82 | ATM (0.38) | CTSSCTSLCTSBAKT1ATR | |
| SCHEMBL21604951 | 0.82 | ATM (0.38) | CTSSCTSLCTSBAKT1ATR | |
| SCHEMBL31226577 | 0.82 | GPR119 (0.41) | GPR119RAF1PIK3CGGRM5XDH | |
| SCHEMBL16398247 | 0.79 | AKT1 (0.35) | GPR119CTSSCTSLCTSBCTSK | |
| SCHEMBL17101625 | 0.74 | RAB9A (0.48) | GPR119AKT1 | |
| SCHEMBL4563796 | 0.74 | CTSS (0.35) | CTSSCTSLCTSBTRPA1CTSK | |
| SCHEMBL21605007 | 0.74 | EGLN2 (0.47) | GPR119RAF1EGLN2GRM5 | |
| SCHEMBL29996741 | 0.74 | EGLN2 (0.47) | GPR119RAF1EGLN2GRM5 | |
| SCHEMBL21598430 | 0.73 | RAF1 (0.35) | RAF1PIK3CGGRM5XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| CN-112585128-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2019243964-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | GPR119 1733/4885RAF1 109/4885CTSS 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.